title: Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy.
authors.affiliation: Department of Surgery, University of Pittsburgh Medical Center, Pennsylvania 15213.
authors.forename: A W
authors.initials: AW
authors.lastname: Thomson
authors.forename: J
authors.initials: J
authors.lastname: Woo
authors.forename: B
authors.initials: B
authors.lastname: Lemster
authors.forename: W
authors.initials: W
authors.lastname: Irish
authors.forename: L L
authors.initials: LL
authors.lastname: Huang
authors.forename: P B
authors.initials: PB
authors.lastname: Carroll
authors.forename: H R
authors.initials: HR
authors.lastname: Rilo
authors.forename: K
authors.initials: K
authors.lastname: Abu-Elmagd
authors.forename: B
authors.initials: B
authors.lastname: Eidelman
mesh_terms: D000328:Adult; D016516:CD4-CD8 Ratio; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D005260:Female; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D015375:Receptors, Interleukin-2; D017493:Leukocyte Common Antigens; D016559:Tacrolimus